Compare Medpace Holdings Inc (MEDP) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Direxion Daily S&P 500 Bull 3X Shares trades at $297.97 (market cap $7.36B). The key difference: Medpace Holdings Inc is far larger — about 2.3× Direxion Daily S&P 500 Bull 3X Shares's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 1,835,467). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| MEDP | SPXL | |
|---|---|---|
Market Cap | $16.82B | $7.36B |
Volume | 223,093 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $630.19 | $301.38 |
52-Week Low | $393.42 | $170.20 |
Typical Hold Time | 14 Days | 32 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
SPXL trades at $297.97, up 0.38% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 66.91 suggesting mild overbought conditions. Support levels begin at $289 with resistance at $297. Recent news highlights S&P 500 valuation debates and profit growth expectations shifting from 35% in 2026 to 15% in 2027.
Outlook remains cautiously optimistic given the ETF's leveraged exposure to S&P 500 momentum. Key risks include market concentration in top holdings and potential profit growth deceleration. The technical setup favors continued upside if $297 resistance breaks, while failure to hold $289 support could signal near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
